SOPHiA GENETICS is a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland.
SOPHiA GENETICS SA is a cloud-native software technology company operating in the healthcare space. Its primary offering is the SOPHiA DDM platform, a cloud-native software platform designed to analyze data and generate insights from multimodal data sets and diagnostic modalities. The platform is used by hospitals, laboratories, and biopharmaceutical companies to support data-driven decision-making in areas such as genomics and diagnostics. The company also provides related solutions, applications, products, and services that complement its core platform. Notably, SOPHiA GENETICS has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom, highlighting its focus on advancing precision medicine through innovative software solutions.
On which stock exchange is SOPHiA GENETICS (SOPH) listed and in what currency?
SOPHiA GENETICS SA is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SOPH. The company trades in US dollars (USD), which is the currency used for its stock transactions and financial reporting. As a Swiss company with a US listing, it provides investors access to its shares through a major American exchange, facilitating liquidity and visibility in the global capital markets.
What sector and industry does SOPHiA GENETICS (SOPH) operate in?
SOPHiA GENETICS SA operates in the Healthcare sector, specifically within the Health Information Services industry. This classification reflects the company's focus on providing software and data analytics solutions that support healthcare providers and researchers in managing and interpreting complex health data. By leveraging cloud-native technology, SOPHiA GENETICS helps hospitals, laboratories, and biopharmaceutical companies derive actionable insights from multimodal data sets, ultimately contributing to advancements in diagnostics and personalized medicine.
Where is SOPHiA GENETICS headquartered and what markets does it serve?
SOPHiA GENETICS SA is headquartered in Rolle, Switzerland, and was incorporated in 2011. The company serves a global customer base, including hospitals, laboratories, and biopharmaceutical companies across multiple regions. Its markets span Switzerland, France, Italy, the rest of Europe, North America, the United States, Latin America, and the Asia-Pacific region. SOPHiA GENETICS reaches its customers through its own direct sales force as well as distributors and industry collaborators, ensuring broad access to its SOPHiA DDM platform and related solutions.
How does SOPHiA GENETICS (SOPH) generate revenue?
SOPHiA GENETICS generates revenue primarily by offering its SOPHiA DDM platform and related solutions, applications, products, and services to hospitals, laboratories, and biopharmaceutical companies. The platform is provided through a cloud-native software-as-a-service (SaaS) model, which typically involves subscription fees or usage-based pricing. Additionally, the company may earn revenue from partnerships and collaborations, such as its agreement with Synnovis to deliver blood-based cancer testing in the United Kingdom. By serving a diverse set of customers across multiple geographies—including Europe, North America, Latin America, and Asia-Pacific—SOPHiA GENETICS monetizes its technology through recurring software revenues and strategic alliances.
On June 17, 2026, the company filed a prospectus supplement for the sale of 10,526,000 ordinary shares, with an option for underwriters to purchase up to an additional 1,578,900 shares at the public offering price.